Dan Gibson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3176465/publications.pdf

Version: 2024-02-01

65 papers	4,356 citations	101543 36 h-index	106344 65 g-index
67 all docs	67 docs citations	67 times ranked	3298 citing authors

#	Article	IF	Citations
1	Study of the DNA binding mechanism and in vitro activity against cancer cells of iron(<scp>iii</scp>) and aluminium(<scp>iii</scp>) kojic acid derivative complexes. Dalton Transactions, 2022, , .	3.3	2
2	Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?. Journal of Inorganic Biochemistry, 2021, 217, 111353.	3.5	70
3	Pt(IV) Anticancer Prodrugs â€“ A Tale of Mice and Men. ChemMedChem, 2021, 16, 2188-2191.	3.2	19
4	Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?. Journal of Medicinal Chemistry, 2021, 64, 11364-11378.	6.4	30
5	Dibenzofuran annulated 1-azepines: Synthesis and cytotoxicity. Synthetic Communications, 2020, 50, 438-445.	2.1	2
6	Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells. Journal of Medicinal Chemistry, 2020, 63, 13861-13877.	6.4	30
7	trans-Platinum(<scp>iv</scp>) pro-drugs that exhibit unusual resistance to reduction by endogenous reductants and blood serum but are rapidly activated inside cells:¹H NMR and XANES spectroscopy study. Dalton Transactions, 2020, 49, 7722-7736.	3.3	21
8	Oxidation of cisâ€Diammineciacetato Pt^{II} with Hydrogen Peroxide Can Give Rise to Two Isomeric Pt^{IV} Products. Chemistry - A European Journal, 2020, 26, 9475-9480.	3.3	5
9	Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules. Inorganic Chemistry, 2020, 59, 5182-5193.	4.0	37
10	A Multiâ€action and Multiâ€target Ru^{II}â€“Pt^{IV} Conjugate Combining Cancerâ€Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers. Angewandte Chemie - International Edition, 2020, 59, 7069-7075.	13.8	172
11	A Multiâ€action and Multiâ€target Ru^{II}â€“Pt^{IV} Conjugate Combining Cancerâ€Activated Chemotherapy and Photodynamic Therapy to Overcome Drug Resistant Cancers. Angewandte Chemie, 2020, 132, 7135-7141.	2.0	25
12	Expanding the Arsenal of Pt^{IV} Anticancer Agents: Multiâ€action Pt^{IV} Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie, 2019, 131, 18386-18391.	2.0	11
13	Expanding the Arsenal of Pt^{IV} Anticancer Agents: Multiâ€action Pt^{IV} Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie - International Edition, 2019, 58, 18218-18223.	13.8	47
14	A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. Journal of Medicinal Chemistry, 2019, 62, 5176-5190.	6.4	48
15	Dualâ€Targeting Dualâ€Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity. Angewandte Chemie, 2019, 131, 8193-8198.	2.0	24
16	Dualâ€Targeting Dualâ€Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity. Angewandte Chemie - International Edition, 2019, 58, 8109-8114.	13.8	81
17	An Anticancer Pt^{IV} Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects. Chemistry - A European Journal, 2019, 25, 5235-5245.	3.3	31
18	Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates. Inorganic Chemistry, 2019, 58, 16676-16688.	4.0	13

#	Article	IF	Citations
19	Multi-action Pt(IV) anticancer agents; do we understand how they work?. Journal of Inorganic Biochemistry, 2019, 191, 77-84.	3.5	124
20	Triple action Pt(<scp>iv</scp>) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. Chemical Science, 2018, 9, 4299-4307.	7.4	121
21	Probing the Interactions of Cytotoxic [Pt(1S,2Sâ€DACH)(5,6â€dimethylâ€1,10â€phenanthroline)] and Its Pt^{IV} Derivatives with Human Serum. ChemMedChem, 2017, 12, 510-519.	3.2	8
22	Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(<scp>iv</scp>) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)]. Dalton Transactions, 2017, 46, 7005-7019.	3.3	43
23	Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates. Scientific Reports, 2017, 7, 3751.	3.3	38
24	The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines. Redox Biology, 2017, 11, 170-175.	9.0	34
25	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie - International Edition, 2017, 56, 11539-11544.	13.8	100
26	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie, 2017, 129, 11697-11702.	2.0	22
27	Platinum(<scp>iv</scp>) anticancer prodrugs â€“ hypotheses and facts. Dalton Transactions, 2016, 45, 12983-12991.	3.3	230
28	A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity. Journal of Medicinal Chemistry, 2016, 59, 9035-9046.	6.4	59
29	Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin. Journal of Inorganic Biochemistry, 2016, 156, 89-97.	3.5	60
30	Pt(<scp>iv</scp>) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chemical Science, 2016, 7, 2381-2391.	7.4	155
31	On the Stability of Pt^{IV} Proâ€Drugs with Haloacetato Ligands in the Axial Positions. Chemistry - A European Journal, 2015, 21, 3108-3114.	3.3	45
32	The role of the catecholic and the electrophilic moieties of caffeic acid in Nrf2/Keap1 pathway activation in ovarian carcinoma cell lines. Redox Biology, 2015, 4, 48-59.	9.0	55
33	New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells. Biochemical Pharmacology, 2015, 95, 133-144.	4.4	78
34	Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands. Journal of Inorganic Biochemistry, 2014, 140, 72-79.	3.5	69
35	In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1465-1475.	3.3	56
36	Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand. Journal of Inorganic Biochemistry, 2013, 126, 46-54.	3.5	6

#	Article	IF	Citations
37	Facile Preparation of Monoâ€• Diâ€•and Mixedâ€Carboxylato Platinum(IV) Complexes for Versatile Anticancer Prodrug Design. Chemistry - A European Journal, 2013, 19, 1672-1676.	3.3	108
38	Platinum(IV) Prodrugs with Haloacetato Ligands in the Axial Positions can Undergo Hydrolysis under Biologically Relevant Conditions. Angewandte Chemie - International Edition, 2013, 52, 6059-6062.	13.8	80
39	Toxicity in tumor cells, DNA binding mode, and resistance to decomposition by sulfur nucleophiles of new dinuclear bifunctional trans-PtII complexes containing long alkane linkers. Pure and Applied Chemistry, 2012, 85, 343-354.	1.9	5
40	Cellular interactions of platinum drugs. Inorganica Chimica Acta, 2012, 393, 75-83.	2.4	60
41	What do we know about the reduction of Pt(IV) pro-drugs?. Journal of Inorganic Biochemistry, 2012, 117, 220-229.	3.5	307
42	Pt(<scp>iv</scp>) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate. Chemical Communications, 2012, 48, 847-849.	4.1	174
43	New reduction pathways for ctc-[PtCl₂(CH₃CO₂)₂(NH₃)(Am)] anticancer prodrugs. Chemical Communications, 2010, 46, 1842-1844.	4.1	76
44	Studies on Cellular Accumulation of Satraplatin and Its Major Metabolite JM118 and Their Interactions with Glutathione. Molecular Pharmaceutics, 2010, 7, 2093-2102.	4.6	27
45	Trans labilization of am(m)ine ligands from platinum(II) complexes by cancer cell extracts. Journal of Biological Inorganic Chemistry, 2009, 14, 387-399.	2.6	28
46	Is Glutathione the Major Cellular Target of Cisplatin? A Study of the Interactions of Cisplatin with Cancer Cell Extracts. Journal of Medicinal Chemistry, 2009, 52, 4319-4328.	6.4	125
47	The mechanism of action of platinum anticancer agentsâ€”what do we really know about it?. Dalton Transactions, 2009, , 10681.	3.3	169
48	Peculiar mechanistic and structural features of the carboplatinâ€“cytochrome c system revealed by ESI-MS analysis. Journal of Biological Inorganic Chemistry, 2008, 13, 755-764.	2.6	35
49	Reduction of cis,trans,cis-[PtCl₂(OCOCH₃)₂(NH₃)₂] by Aqueous Extracts of Cancer Cells. Journal of Medicinal Chemistry, 2007, 50, 5554-5556.	6.4	100
50	Cationic Nonsymmetric Transplatinum Complexes with Piperidinopiperidine Ligands. Preparation, Characterization, in Vitro Cytotoxicity, in Vivo Toxicity, and Anticancer Efficacy Studies. Journal of Medicinal Chemistry, 2006, 49, 4665-4673.	6.4	32
51	The trans labilization of cis-[PtCl2(13CH3NH2)2] by glutathione can be monitored at physiological pH by [1H,13C] HSQC NMR. Journal of Biological Inorganic Chemistry, 2006, 11, 179-188.	2.6	20
52	Mass spectrometric studies of the formation and reactivity oftrans-[PtCl2(Am)(piperidinopiperidine)] Â· HCl complexes with ubiquitin. Rapid Communications in Mass Spectrometry, 2005, 19, 3666-3672.	1.5	9
53	Ligand effects on the binding of cis- and trans-[PtCl2Am1Am2] to proteins. Journal of Biological Inorganic Chemistry, 2003, 8, 167-175.	2.6	35
54	Drugâ€“DNA interactions and novel drug design. Pharmacogenomics Journal, 2002, 2, 275-276.	2.0	44

#	Article	IF	Citations
55	Novel Soluble Cationictrans-Diaminedichloroplatinum(II) Complexes that Are Active against Cisplatin Resistant Ovarian Cancer Cell Lines. Journal of Medicinal Chemistry, 2002, 45, 5189-5195.	6.4	104
56	Novel Apoptosis-Inducingtrans-Platinum Piperidine Derivatives:Â Synthesis and Biological Characterization. Journal of Medicinal Chemistry, 2002, 45, 5196-5204.	6.4	64
57	Interactions of cisplatin and transplatin with proteins. Journal of Inorganic Biochemistry, 2002, 91, 306-311.	3.5	118
58	Cisplatinâ^'Protein Adducts Are Efficiently Removed by Glutathione but Not by 5â€˜-Guanosine Monophosphate. Journal of the American Chemical Society, 2001, 123, 3171-3172.	13.7	69
59	A mass spectral study of the binding of the anticancer drug cisplatin to ubiquitin. European Journal of Mass Spectrometry, 1999, 5, 501.	0.7	77
60	Monofunctional platinum amine complexes destabilize DNA significantly. FEBS Journal, 1998, 256, 253-260.	0.2	35
61	Anthraquinone intercalators as carrier molecules for second-generation platinum anticancer drugs. European Journal of Medicinal Chemistry, 1997, 32, 823-831.	5.5	27
62	Acylphosphonamidates and ?-hydroxyiminophosphonamidates. Synthesis of N-acylphosphordiamidates by Beckmann rearrangement. Crystal structure of (E)-?-hydroxyiminobenzyl-1-pyrrolidinylphosphinate. Heteroatom Chemistry, 1996, 7, 515-520.	0.7	14
63	Rearrangement and Fragmentation Reactions of Î±-Hydroxyiminophoshinates. On the Nature of the Metaphosphonate Intermediate Involved in Phosphonylations by Î±-Hydroxyiminophosphinate. Phosphorus, Sulfur and Silicon and the Related Elements, 1990, 49-50, 81-84.	1.6	6
64	Structure and Reactivity of 2-Hydroxyiminobenzyl-2-oxo-4,4,5,5-tetramethyl[1,3,2]dioxaphospholanes. Phosphorus, Sulfur and Silicon and the Related Elements, 1989, 41, 433-437.	1.6	4
65	X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]. Science, 1985, 230, 412-417.	12.6	410